Oppenheimer Asset Management Inc. Has $3.33 Million Stock Position in Natera, Inc. $NTRA

Oppenheimer Asset Management Inc. grew its stake in Natera, Inc. (NASDAQ:NTRA) by 11.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 19,736 shares of the medical research company’s stock after buying an additional 1,992 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Natera were worth $3,334,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its position in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Natera in the 1st quarter valued at about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Natera by 140.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock valued at $177,298,000 after purchasing an additional 732,156 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Natera by 9.9% during the first quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after buying an additional 660,538 shares during the period. Finally, Ninety One UK Ltd grew its holdings in shares of Natera by 149.1% during the second quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock worth $95,111,000 after buying an additional 336,985 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Activity

In related news, Director Gail Boxer Marcus sold 2,496 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $133.17, for a total transaction of $332,392.32. Following the transaction, the director directly owned 5,763 shares of the company’s stock, valued at approximately $767,458.71. The trade was a 30.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total value of $459,222.50. Following the completion of the sale, the director owned 6,015 shares in the company, valued at approximately $1,004,444.85. This trade represents a 31.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 57,374 shares of company stock valued at $9,108,022. 5.63% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research reports. Wells Fargo & Company assumed coverage on Natera in a research note on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 target price on the stock. Zacks Research lowered shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. BNP Paribas Exane upgraded shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price for the company in a report on Monday. Evercore ISI upgraded shares of Natera to a “strong-buy” rating and set a $170.00 price target on the stock in a research note on Monday, July 28th. Finally, Morgan Stanley reissued an “overweight” rating and set a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Natera presently has an average rating of “Moderate Buy” and an average price target of $194.89.

Natera Trading Down 1.4%

NASDAQ NTRA opened at $189.57 on Wednesday. The firm has a market capitalization of $26.02 billion, a P/E ratio of -99.25 and a beta of 1.74. The firm’s fifty day moving average price is $172.50 and its two-hundred day moving average price is $161.04. Natera, Inc. has a 1 year low of $119.29 and a 1 year high of $198.99.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm’s revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.